Osteoarthritis
- PMID: 39755397
- DOI: 10.1016/S0140-6736(24)02322-5
Osteoarthritis
Erratum in
-
Department of Error.Lancet. 2025 Jun 28;405(10497):2278. doi: 10.1016/S0140-6736(25)01292-9. Lancet. 2025. PMID: 40581483 No abstract available.
Abstract
Osteoarthritis is a heterogeneous disorder that is increasingly prevalent largely due to aging and obesity, resulting in a major disease burden worldwide. Knowledge about the underlying aetiology has improved, with increased understanding of the role of genetic factors, the microbiome, and existence of different pain mechanisms. However, this knowledge has not yet been translated into new treatment options. New evidence has questioned the efficacy of recommended treatments, such as therapeutic exercise programmes and the focus on weight loss, but managing obesity and maintaining activity remain important for the prevention and management of osteoarthritis. Approaches should consider individual and cultural preferences and resource availability to increase patient and community engagement, and optimise outcomes worldwide. Most of the focus has been on established osteoarthritis where management is primarily directed at relieving symptoms. The search for the much needed effective treatments that improve both symptoms and structure, often referred to as disease-modifying osteoarthritic drugs, is ongoing. Promising data indicate that targeting inflammation is effective in hand osteoarthritis.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests MK received grants from IMI-APPROACH and the Dutch Arthritis Society (paid to their institution); royalties from Wolters-Kluwer and Springer Verlag (paid to their institution); fees for consultancy and participation in advisory boards from Pfizer, the Centre for Human Drug Research, Novartis, UCB, GlaxoSmithKline, and Peptinov (paid to their institution); payments for lectures from Novartis (paid to their institution); holds leadership roles as a member of the OARSI board (2017–22); is a member of the European Alliance of Associations for Rheumatology council (chair advocacy committee); and is President of the Dutch Society for Rheumatology. FC received grants from the National Health and Medical Research Council, Magellan Stem Cells and the Melbourne Stem Cell centre, Arthritis Australia, Xalud Therapeutics Australia, and Paradigm BioPharmaceuticals (paid to their institution). MN declares no competing interests. The Osteoarthritis Research Society International board provided support to the authors to attend their meeting.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
